Literature DB >> 28605998

Primary Cutaneous CD4+ Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series.

Martina Maurelli1, Chiara Colato2, Paolo Gisondi1, Giampiero Girolomoni1.   

Abstract

BACKGROUND: Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (CD4+ PCSM-LPD) is defined by a predominance of small- to medium-sized CD4+ pleomorphic T cells and a favorable clinical course.
OBJECTIVE: We performed a retrospective analysis of 6 patients with CD4+ PCSM-LPD and reviewed the literature to address questions about its diagnosis, treatment, and prognosis.
METHODS: Patients were 3 men and 3 women with a median age of 50 years. All patients presented with a single erythematous nodule, localised on the head in 4 patients and the upper trunk in 2 cases. No patients showed extracutaneous disease at any evaluation. Histopathologic features were characterised by nodular, diffuse, or, in 1 case, a superficial dense infiltrate of small/medium-sized pleomorphic CD4+/PD1+ T lymphocytes. T-cell receptor clonality was demonstrated in 5 cases. Treatment was surgical excision in 5 cases and radiotherapy in 1 case.
RESULTS: All patients achieved complete resolution without relapses, during a median follow-up of 3 years. A review of the literature confirmed that CD4+ PCSM-LPD presents predominantly with a solitary nodular lesion on the face, neck, or upper trunk in adult patients. Surgical excision is the preferred treatment. Spontaneous resolution after biopsy may occur.
CONCLUSIONS: CD4+ PCSM-LPD is a rare disorder with a favorable course.

Entities:  

Keywords:  diagnosis; lymphoma; lymphoproliferative disease; prognosis; therapy

Mesh:

Year:  2017        PMID: 28605998     DOI: 10.1177/1203475417715209

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  1 in total

1.  Case for diagnosis. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder.

Authors:  Flávia de Oliveira Valentim; Cristiano Claudino Oliveira; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2019 Jan-Feb       Impact factor: 1.896

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.